The European surgical hemostat, internal tissue sealant, and adhesion barrier market remains both dynamic and vastly underpenetrated across the region in 2011 and is heavily influenced by numerous competing factors that will contribute to overall revenue growth. Procedures in which these products are most commonly used - cardiovascular and reconstructive procedures - will continue to be driven by favorable demographics, leading to increased procedure volumes. Procedure increases in this space will, however, be hindered somewhat due to the increased usage of alternative low-cost treatment options for controlling blood flow, sealing tissue, and preventing the formation of adhesions postoperatively. Cost-consciousness among facilities in Europe will continue to restrict revenue expansion and will be the primary limiting factor. This fiscal restraint will cause physicians to limit their usage of these devices, slowing device penetration in each segment to some extent. The use of public tenders and group purchasing organizations will cause declines in average selling prices (ASPs), limiting growth in the European surgical hemostat, internal tissue sealant, and adhesion barrier market. Despite these negative trends, the needs of physicians continue to go unmet by the current product offerings; products in this space provide benefits beyond their initial cost, which has helped these markets garner increased attention from hospitals and physicians. With the continued development of intuitive, technologically advanced products in all three segments, current market players continue to jockey for position by increasing procedural applicability for existing products while performing clinical trials to further the boundaries of their new products. Positive clinical data along with increased penetration by these devices across all three segments will help to expand the European surgical hemostat, internal tissue sealant, and adhesion barrier market through 2016.